Meloxivet® Cat

Oral solution.

Analgesic and anti-inflammatory.

Each mL of oral solution contains:
Meloxicam. ……………………………….. 0.5 mg
Excipients q.s…. ……………………… 1 mL

Indicated for the control of pain and inflammation associated with acute painful locomotor disorders and osteoarthritis in cats.

Cats.

Oral.

Administer an initial dose of 0.2 mL per kilogram of body weight on the first day of treatment, followed by a maintenance dose of 0.1 mL per kilogram of body weight every 24 hours. These doses are equivalent to administering an initial dose of the active ingredient of 0.1 mg/kg body weight on the first day of treatment, followed by a maintenance dose of 0.05 mg/kg body weight every 24 hours. The duration of acute treatment is 5 days, which can be prolonged for up to 14 days in feline osteoarthritis. The response to long-term therapy should be monitored at regular intervals by a veterinarian.

The solution should be administered using the dosing syringe included in the package, depending on the weight of each animal.

Administer mixed with a portion of food or directly into the cat’s mouth. Wash and dry the dosing syringe between administrations.

• Keep out of reach of children and pets.
• Special care should be taken regarding dosage accuracy in cats. Do not exceed the indicated dose.
• Avoid use in dehydrated, hypovolemic or hypotensive animals, since there is a greater potential risk of developing renal toxicity.
• Simultaneous administration of drugs with nephrotoxic potential should be avoided.
• Meloxicam, like all non-steroidal anti-inflammatory drugs (NSAIDs), should be used with caution in animals with hepatic, cardiac or renal insufficiency and animals with bleeding disorders. Hypotension, high doses, hypovolemia, sodium depletion and inhalation anesthesia appear to increase the risk of renal toxicity from NSAIDs.
• Animals with pre-existing gastrointestinal problems may be at increased risk of adverse effects from NSAIDs.
• Treatment should be discontinued if the expected clinical response is not observed.

• Do not administer in cats with known hypersensitivity to Meloxicam or other non-steroidal anti-inflammatory drugs (NSAIDs).
• Do not administer to cats under 4 months of age and weighing less than 450 grams, since safety has not been evaluated in them.
• Do not use in cats with gastrointestinal disorders such as irritation and bleeding, hepatic, cardiac or renal dysfunction and bleeding disorders.
• Do not administer to pregnant females, lactating females or breeding animals.
• Do not administer in conjunction with other NSAIDs or glucocorticoids.

The main adverse effects are gastrointestinal effects, such as vomiting, diarrhea, gastrointestinal ulceration, loss of appetite, as well as behavioral changes and lethargy, which occur in approximately 10% of the cases. These effects are in most cases transient and disappear after the end of treatment. If adverse effects occur, discontinue treatment and consult a Veterinarian.

• Co-administration with Amiodarone, Digoxin, Fluconazole or Sulfonamides could increase Meloxicam concentrations.
• Some NSAIDs can reduce the effects on blood pressure of angiotensin-converting enzyme inhibitors (ACE inhibitors) or Amlodipine.
• Co-administration with anticoagulants (e.g., Heparin or Warfarin), tricyclic antidepressants (e.g., Amitriptyline, Clomipramine), Clopidogrel, selective serotonin reuptake inhibitors (e.g., Fluoxetine) or Pentoxifylline may increase the risk of bleeding or hemorrhage of Meloxicam.
• Co-administration with Cyclosporine (systemic), diuretics (e.g. Furosemide or Hydrochlorothiazide), nephrotoxic drugs (e.g. Furosemide, Amphotericin B and aminoglycosides) or inhalation anesthetics (e.g. Isoflurane or Sevoflurane), could increase the risk of nephrotoxicity of Meloxicam.
• Co-administration with other NSAIDs, corticosteroids (e.g., Dexamethasone, Prednisolone), bisphosphonates (e.g., Alendronate) and salicylates (e.g., Bismuth Subsalicylate), may exacerbate the gastrointestinal adverse effects of Meloxicam.
• Meloxicam may increase concentrations of fluoroquinolones (e.g. Enrofloxacin, Marbofloxacin), increasing the risk of central nervous system (CNS) toxicity.
• Co-administration with Leflunomide may increase the risk of hepatotoxicity.
• Concomitant use of NSAIDs with Methotrexate may increase the risk of myelosuppression, nephropathy, hepatotoxicity and gastrointestinal toxicity; use them together with extreme caution.

• Do not handle by persons hypersensitive to Meloxicam or other NSAIDs.
• Do not smoke, eat or drink during administration of the product.
• In case of contact with skin, eyes or mucous membranes, wash immediately with plenty of water. In case of irritation, go to a medical center and show the product insert.
• In case of accidental ingestion, go immediately to a medical center and show the product insert.

Empty containers can be discarded as household waste, without any special precautions. Do not dispose of containers with product residues on the ground or in waterways. For expired or unused products, contact the manufacturing laboratory.

Store at room temperature below 25°C. Do not refrigerate or freeze. Once opened, use within 28 days. Discard the unused product after that period of time.

Sale by prescription to the Veterinary Doctor.

VETERINARY USE
KEEP OUT OF REACH OF CHILDREN AND PETS

Chile: Reg. SAG NO. 2690
Peru: Reg. SENASA F.99.32.I.0130

Bottle with 20 mL

Laboratorio Drag Pharma Chile Invetec S.A.
Lautaro N° 300. Quilicura. Santiago. Chile.